KBC Securities - EXOR N.V. (EXO) ... Morning Notes : FAST NA, EXO NA

Report

KBC Securities

Hilde Van Boxstael ...

Livio Luyten
Wim Lewi

Morning Notes : FAST NA, EXO NA

: FAST NA, EXO NA

10/10/2025 1 EN

Underlyings

EXOR N.V.

See profile

NL0012059018 Netherlands

Fastned

Fastned BV is a company based in the Netherlands that owns and develops charging stations. The Company offers charging solutions to electric transportation through solar and wind energy. It serves customers in Europe.

See profile

NL0013654809 Euronext Amsterdam Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Hilde Van Boxstael

Livio Luyten

Wim Lewi

Other Reports on these Companies

ING Financial Markets

Benelux Morning Notes

Exor: CMD of the prancing horse. Fastned: 3Q25 preview. Kinepolis: Peer Cineplex September 2025 box office revenue at 85% of 2019, up 7% YoY. Staffing: Hays' 1Q26 trading update. Var Energi: Ramping up production as planned

10h / 54m 10h / 54m 1 EN

KBC Securities

Dynamic Top Pick List Update October: Removing VGP – Adding Shurgard and Wolters Kluwer

In this October update of our Dynamic Top Pick List we are removing VGP while adding Shurgard and Wolters Kluwer. Since its recent inclusion in our Dynamic Top Pick List in July-25, VGPs share rose by 10.6%. While we still believe there is significant upside to the share price, we don't see short term catalysts. In fact, the macro picture remains cloudy with the jury still out on the impact of tariffs and the erratic US policy shifts. Also, we are a bit concerned that competition in Western Europe increases after we attended the CTP capital markets day. We decided to add Shurgard to the Dyna...

October 2, 2025 October 2, 2025 1 EN

Amoéba Now full speed ahead to commercial launch of its biocontrol solution in ‘26

First-half result numbers overshadowed by the various milestones achieved over the past two years by its biocontrol solution (with final approval of the active substance by the European Commission and the signing of a strategic distribution agreement with Koppert) now enables them to launch its commercialisation in 2026. The US EPA (Environmental Protection Agency) decision on the application for federal marketing authorisation in the US for AXPERA, which has been delayed for reasons beyond Amoéba's own control, is expected in 1Q26. We also welcome the interest in its cosmetic ingredient, bo...

12h / 19m 12h / 19m 1 EN

Hilde Van Boxstael ... (+5)

Hilde Van Boxstael
Jacob Mekhael
Livio Luyten
Thibault Leneeuw
Wim Lewi

Morning Notes : FAGR BB, IVA FP, SOF BB, ENRGY BB

: FAGR BB, IVA FP, SOF BB, ENRGY BB

October 9, 2025 October 9, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : FAST NA, EXO NA

We are a financial services provider for several types of professional clients, each with distinct needs.

Benelux Morning Notes

Dynamic Top Pick List Update October: Removing VGP – Adding Shurgard and Wolters Kluwer

Amoéba Now full speed ahead to commercial launch of its biocontrol solution in ‘26

Morning Notes : FAGR BB, IVA FP, SOF BB, ENRGY BB

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe